Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Merus NV - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
MRUS
Nasdaq
8731
https://merus.nl/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Merus NV
Merus N.V. (NASDAQ:MRUS) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
- May 11th, 2024 1:04 pm
Investors push Merus (NASDAQ:MRUS) 5.0% lower this week, company's increasing losses might be to blame
- May 10th, 2024 12:35 pm
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
- May 8th, 2024 8:15 pm
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
- May 6th, 2024 8:05 pm
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
- Apr 29th, 2024 2:00 pm
Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?
- Apr 26th, 2024 11:58 am
Will Merus N.V. (MRUS) Report Negative Q1 Earnings? What You Should Know
- Apr 25th, 2024 2:01 pm
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
- Apr 24th, 2024 2:00 pm
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
- Apr 8th, 2024 4:00 pm
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
- Apr 3rd, 2024 12:00 pm
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
- Mar 20th, 2024 11:37 am
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
- Mar 6th, 2024 1:00 pm
Gilead bets on ‘trispecifics’ in latest cancer drug deal
- Mar 6th, 2024 11:15 am
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
- Mar 5th, 2024 9:30 pm
Merus Full Year 2023 Earnings: Misses Expectations
- Mar 5th, 2024 6:49 pm
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
- Mar 4th, 2024 1:00 pm
Earnings Update: Merus N.V. (NASDAQ:MRUS) Just Reported And Analysts Are Trimming Their Forecasts
- Mar 2nd, 2024 12:36 pm
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
- Feb 28th, 2024 9:15 pm
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Feb 20th, 2024 3:00 pm
15 Top Performing European Stocks So Far in 2024
- Feb 16th, 2024 8:57 am
Scroll